WO2016061772A1 - Composés nargénicine et leurs utilisations de comme agents antibactériens - Google Patents

Composés nargénicine et leurs utilisations de comme agents antibactériens Download PDF

Info

Publication number
WO2016061772A1
WO2016061772A1 PCT/CN2014/089204 CN2014089204W WO2016061772A1 WO 2016061772 A1 WO2016061772 A1 WO 2016061772A1 CN 2014089204 W CN2014089204 W CN 2014089204W WO 2016061772 A1 WO2016061772 A1 WO 2016061772A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
arya
ring
optionally substituted
compound
Prior art date
Application number
PCT/CN2014/089204
Other languages
English (en)
Inventor
Katherine Young
David B. Olsen
Sheo B. Singh
Jing Su
Robert R. Wilkening
James M. Apgar
Dongfang Meng
Dann Parker
Mihir Mandal
Lihu Yang
Ronald E. Painter
Qun Dang
Takao Suzuki
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to PCT/CN2014/089204 priority Critical patent/WO2016061772A1/fr
Priority to MX2017005271A priority patent/MX2017005271A/es
Priority to EP15853228.3A priority patent/EP3209667A4/fr
Priority to CA2964377A priority patent/CA2964377A1/fr
Priority to BR112017008101A priority patent/BR112017008101A2/pt
Priority to KR1020177013260A priority patent/KR20170070197A/ko
Priority to RU2017117253A priority patent/RU2017117253A/ru
Priority to US15/517,570 priority patent/US9944654B2/en
Priority to PCT/US2015/056627 priority patent/WO2016064982A1/fr
Priority to CN201580069971.4A priority patent/CN107108646A/zh
Priority to AU2015335992A priority patent/AU2015335992A1/en
Priority to JP2017521550A priority patent/JP2017533200A/ja
Publication of WO2016061772A1 publication Critical patent/WO2016061772A1/fr
Priority to US15/910,571 priority patent/US10144741B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • the present invention relates to novel nargenicin compounds useful for the treatment of bacterial infections, particularly mycobacterial infections.
  • the invention also relates to methods of use of nargenicin compounds for the treatment of mycobacterial infectionssuch as those caused by Mycobacteria tuberculosis.
  • nargenicins are a class of polyketide macrolide antibiotics with a tricyclic lactone containing a unique ether bridge. See Kallmerten, 1995, Studies in Natural Products Chemistry 17:283-310. The first nargenicin, nargenicin A 1 , was originally isolated from Nocardia argentinensis. See Celmer et al. , 1980, J. Am. Chem. Soc. 102:4203–4209. Nargenicin has been demonstrated to be effective towards gram-positive bacteria and, in particular, has been shown to have strong antibacterial activity against methicillin-resistantStaphylococcus aureus. SeeSohnget al. , 2008, Arch Pharm Res31:1339–1345 and Korean Patent Application No.
  • KR2009093733A It has also been contemplated for use as a treatment for neoplastic diseases and neurodegenerative diseases. See, e. g. , Kim et al. , 2009, Biochem Pharmacol 77:1694-1701, and Korean Patent Application No. KR2010071835A.
  • nargenicin B 1 nargenicin B 1
  • nargenicin B 2 nargenicin B 3
  • nargenicin C 1 nargenicin C 1
  • Mycobacterium is a genus of bacterium, neither truly gram-positive nor truly gram-negative, including pathogens responsible for tuberculosis (M. tuberculosis) and leprosy (M.leprae) .
  • Tuberculosis (TB) in particular, despite the availability of anti-TB drugs such as isoniazide and rifampin, is considered to be one of the world's deadliest diseases. According to World Health Organization, in 2012, there were 8.6 million new TB cases and 1.3 million TB deaths. See, Global tuberculosis report 2013 published by the World Health Organization. Complicating the TB epidemic is the rising tide of multi-drug-resistant strains, and the deadly association with HIV.
  • Mycobacteria other than M. tuberculosis are increasingly found in opportunistic infections that plague the AIDS patient.
  • Organisms from the M. avium-intracellulare complex (MAC) especially serotypes four and eight, account for 68%of the mycobacterial isolates from AIDS patients.
  • Enormous numbers of MAC are found (up to 1010 acid-fast bacilli per gram of tissue) , and consequently, the prognosis for the infected AIDS patient is poor.
  • the present invention is directed to certain novel nargenicin compounds which are DnaE inhibitors and/or have antibacterial activity.
  • the compounds, and their pharmaceutically acceptable salts can be useful, for example, for the treatment of bacterial infections, for example, mycobacterial infections. More particularly, the present invention includes compounds of Formula I, or a pharmaceutically acceptable salt thereof:
  • Y is O, –NR B , S or –SO 2 ;
  • Z is O or –NR 0 ;
  • R 0 is H, C 1-6 alkyl, C 3-6 cycloalkyl, AryA, or HetA;
  • R 1b is H, C 1-6 alkyl, or C 2-6 alkenyl
  • anyR A alkyl is optionally substituted with 1 or 2 substituentsindependently selected from halogen, –NR x R y , –N + R x R y R z , –SCH 3 , AryA, and HetA; and
  • any R A alkenyl is optionally substituted with AryA;
  • R x , R y and R z are independently H or C 1-6 alkyl
  • R v and R w are C 1-6 alkyl substituted with 1 to 3 –OH substituents
  • R B alkyl is optionally substituted with –NR x R y or –OH;
  • R C is H, C 1-6 alkyl, or C 3-6 cycloalkyl
  • R b is C 1-6 alkyl, C 3-6 cycloalkyl, AryA, or HetA;
  • R 2a is halogen, –NR B R C or –OR 2’ ;
  • R 2b is H
  • R 3 is H
  • R 4b is H
  • R 3 and R 4a together form a bond
  • R z is –NR x R y , –NH–C 3-6 cycloalkyl, disulfanylC 1-6 alkylamine, AryA, or HetA; or
  • R 5a is H, –C 1-6 alkyl, –OH, or AryA;
  • R 5b is H
  • R 6a is H, –C 1-6 alkyl, –OH, or AryA;
  • R 6b is H
  • R 7 is –OR 8 or –NR B R C ;
  • R 8 is H or C 1-6 alkyl
  • R 9 , R 10 and R 11 are independently H, –CH 3 , or –OH;
  • R 12a is –CH 3 or –CH 2 OH
  • R 12b and R 13 are H, or together form a bond, or together with the atoms to which they are connected form a cyclopropyl ring;
  • R 14 is H or C 1-6 alkyl
  • AryA is
  • AryB is
  • a 4-to 6-membered saturated or monounsaturated monocyclic ring with 1 or 2 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with 1 or 2 substituents independently selected from halogen, C 1- C 6 alkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 aminoalkyl, C 1- C 6 alkoxy, –(CH 2 ) 0-3 C ( O) NR x R y , cyano, –NH 2 , –OH, and– (CH 2 ) 0-3 HetC; or
  • Y and Z are O;
  • R 1b , R 2b , R 9 , R 10 , R 11 and R 14 are H;
  • R 2a is —OH
  • R 5a and R 6a together form a bond
  • R 12b and R 13 together form a bond
  • R 7 is —OH or –OCH 3 ;
  • R 12a is –CH 3 ;
  • the present invention also relates to a pharmaceutical composition for treating a bacterial infection, particularly anM. tuberculosis infection, in a subject, comprising the compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention is also directed to 1) methods of treating tuberculosis in a subject in need of treatment thereof, comprising administering to the subject an effective amount of a nargenicin compound; and 2) uses of a nargenicin compound for the treatment of tuberculosis.
  • the present invention is based, in part, on the surprising result that nargenicin, previously known to be narrowly active against gram-positive, is cidal against mycobacteria and, therefore, potentially useful in treating tuberculosis.
  • Nargenicins were originally developed for use in treating gram-positive bacterial infections, particularly, methicillin-resistant S. aureus infections. Nargenicins have also been reported to have potential activity for neoplastic diseases and neurogenerative diseases.
  • the target for nargenicins appears to be DnaE, a homolog of the E. coli holoenzyme alpha subunit. As shown in the Examples, in vitro MIC testing of nargenicin compounds against a variety of aerobic bacteria revealed excellent potency.
  • the present invention includes compounds of Formula I, wherein the compounds are suitable for use for the treatment of bacterial infections, particularly mycobacterial infections.
  • a compound of the invention does not include any of the compounds disclosed in Megerlein et al. , 1982, J. Antibiotics 35:254-255; Kallmerten, 1995, Studies in Natural Products Chemistry 17:283-310; and U. S. Pat. Nos.
  • Nargenicin A 1 18-deoxynargenicin A 1 , 18-deoxy-18-oxonargenicin A 1 , 18-chloro-18-deoxynargenicin A 1 , 18-azido-18-deoxynargenicin A 1 , 18-O-thiocarbonyl-1’ -imidazolenargenicin A 1 , Nargenicin B 1 , Nargenicin B 2 , Nargenicin B 3 , Nargenicin C 1 , and nodusmicin.
  • Representative structures include:
  • such compounds are nargenicin compounds which can be used in the methods of the invention.
  • the compound is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein Y is O, and the other groups are as provided in the general formula for formula I.
  • the compound has the formula
  • the compound is a compound of formula I or Ia, or a pharmaceutically acceptable salt thereof, wherein
  • R 1b is H
  • R A alkyl is optionally substituted with one or two substituentsindependently selected from halogen, –SCH 3 , AryA, and HetA;
  • R g alkyl is optionally substituted by 1 to 3 –NR x R y or –OH substituents or 1
  • the compound is a compound of formula Ib, or a pharmaceutically acceptable salt thereof,
  • R 2a is halogen or –OR 2’ ;
  • R 2b is H
  • R 5a is H or –OH
  • R 5b is H
  • R 6a is H or –OH
  • R 6b is H
  • R 5a and R 6a together form a bond or together with the atoms to which they are attached form an oxirane
  • R 7 is –OR 8 ;
  • R 8 is H or C 1-6 alkyl
  • AryA is
  • AryB is
  • a 8-membered saturated bicyclic ring with 2 N, or N as a quaternary salt, ring atoms, optionally substituted with 1 substituent selected from C 1- C 6 alkyl, –CH 2 C ( O) NH 2 , and – (CH 2 ) 3 HetC;
  • the compound is a compound of formula I, Ia, or Ib, or a pharmaceutically acceptable salt thereof, wherein
  • AryA is
  • the compound is a compound of formula I, Ia, or Ib, or a pharmaceutically acceptable salt thereof, wherein
  • R 4a is H, –NH 2 , –OH, cyano
  • R 4b is H
  • the compound is a compound of formula I, Ia, or Ib, or a pharmaceutically acceptable salt thereof, wherein
  • R 2a is —OH, F,
  • R 2b is H
  • the compound is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1a is H, methyl, ethyl, phenyl,
  • R 1b is H.
  • the compound is a compound of formula Ic, or a pharmaceutically acceptable salt thereof,
  • anyR A alkyl is optionally substituted with 1 or 2 substituentsindependently selected from halogen, –NR x R y , –N + R x R y R z , –SCH 3 , AryA, and HetA; and
  • R A alkenyl is optionally substituted with AryA;
  • R b is C 1-6 alkyl, C 3-6 cycloalkyl, AryB, or HetB;
  • R x , R y and R z are independently H or C 1-6 alkyl
  • R v and R w are C 1-6 alkyl substituted with 1 to 3 –OH substituents
  • AryA is
  • AryB is
  • the compound is a compound of formula Ic, or a pharmaceutically acceptable salt thereof,
  • AryB is pyridinyl orimidazolyl, wherein a N ring atom is optionally in the form of a quaternary salt, and wherein AryB is optionally substituted with –CH 3 .
  • HetA is morpholinyl or 1, 4-diazabicyclo [2.2.2] octane.
  • the compound is a compound of formula Ic, or a pharmaceutically acceptable salt thereof,
  • the compound of the invention is selected from the exemplary species depicted in EXAMPLES 1 to 142 and 145 to 213shown below, and pharmaceutically acceptable salts thereof.
  • the compound of the invention is selected from the exemplary species depicted in EXAMPLES 90, 94, 100, 108, 109, 118, and 204 shown below, and pharmaceutically acceptable salts thereof.
  • R p is 1 to 4
  • R p includes any of the substutitions for HetA
  • R q is H or –CH 3 .
  • a pharmaceutical composition comprising an effective amount of a compound of Formula I, Ia, Ib, or Ic, as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • (c) The pharmaceutical composition of (b) , wherein the second antibiotic is amikacin, para-aminosalicylic acid, capreomycin, cycloserine, ethionamide, ethambutol, isoniazid, levofloxacin, moxifloxacin, pyrazinamide, rifabutin, rifampin, rifapentine, orstreptomycin.
  • the second antibiotic is amikacin, para-aminosalicylic acid, capreomycin, cycloserine, ethionamide, ethambutol, isoniazid, levofloxacin, moxifloxacin, pyrazinamide, rifabutin, rifampin, rifapentine, orstreptomycin.
  • a pharmaceutical composition which is (i) a compound of formula I, Ia, Ib, or Ic, or a pharmaceutically acceptable salt thereof, and (ii) a second antibiotic, wherein the compound of formula I, Ia, Ib, or Ic, and the second antibiotic are each employed in an amount that renders the combination effective for inhibiting DnaE, or for treating or preventing bacterial infection.
  • a method for inhibiting DnaE and/or treating a bacterial infection which comprises administering to a subject in need of such treatment an effective amount of a compound of Formula I, Ia, Ib, or Ic, or a pharmaceutically acceptable salt thereof.
  • a method for preventing and/or treating a bacterial infection which comprises administering to a subject in need of such treatment an effective amount of a compound of Formula I, Ia, Ib, or Ic, or a pharmaceutically acceptable salt thereof.
  • a method for treating a bacterial infection which comprises administering to a subject in need of such treatment a therapeutically effective amount of the composition of (a) , (b), (c) , (d) , or (e) .
  • a method for preventing and/or treating a mycobacterial infection which comprises administering to a subject in need of such treatment an effective amount of a composition comprising a nargenicin compound, or a pharmaceutically acceptable salt thereof.
  • composition is a composition of (a) , (b) , (c) , (d) , or (e) .
  • the present invention also includes a compound of Formula I, Ia, Ib, or Ic, or a pharmaceutically acceptable salt thereof, (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation (or manufacture) of a medicament for, medicine orinhibiting DnaE or treating bacterial infection, particularly a mycobacterial infection.
  • the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents includingamikacin, para-aminosalicylic acid, capreomycin, cycloserine, ethionamide, ethambutol, isoniazid, levofloxacin, moxifloxacin, pyrazinamide, rifabutin, rifampin, rifapentine, or streptomycin.
  • one or more second therapeutic agents includingamikacin, para-aminosalicylic acid, capreomycin, cycloserine, ethionamide, ethambutol, isoniazid, levofloxacin, moxifloxacin, pyrazinamide, rifabutin, rifampin, rifapentine, or streptomycin.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a) - (l) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, sub-embodiments, classes or sub-classes described above.
  • the compound may optionally be used in the form of a pharmaceutically acceptable salt in these embodiments.
  • each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound or salt and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (l) above are understood to include all embodiments of the compounds and/or salts, including such embodiments as result from combinations of embodiments.
  • Additional embodiments of the present invention include each of the pharmaceutical compositions, combinations, methods and uses set forth in the preceding paragraphs, wherein the compound of the present invention or its salt employed therein is substantially pure.
  • Alkyl means saturated carbon chains which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise.
  • Other groups having the prefix “alk” such as alkoxy and alkanoyl, also may be linear or branched, or combinations thereof, unless the carbon chain is defined otherwise.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-and tert-butyl, pentyl, hexyl, heptyl, octyl, and the like.
  • alkenyl means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched, or combinations thereof, unless otherwise defined. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
  • Antibiotic refers to a compound or composition which decreases the viability of a microorganism, or which inhibits the growth or proliferation of a microorganism.
  • the phrase "inhibits the growth or proliferation” means increasing the generation time (i. e. , the time required for the bacterial cell to divide or for the population to double) by at least about 2-fold.
  • Preferred antibiotics are those which can increase the generation time by at least about 10-fold or more (e. g. , at least about 100-fold or even indefinitely, as in total cell death) .
  • an antibiotic is further intended to include an antimicrobial, bacteriostatic, or bactericidal agent.
  • “About” when modifying the quantity (e. g. , kg, L, or equivalents) of a substance or composition, or the value of a physical property, or the value of a parameter characterizing a process step (e. g. , the temperature at which a process step is conducted) , or the like refers to variation in the numerical quantity that can occur, for example, through typical measuring, handling and sampling procedures involved in the preparation, characterization and/or use of the substance or composition; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make or use the compositions or carry out the procedures; and the like.
  • the quantity e. g. , kg, L, or equivalents
  • a parameter characterizing a process step e. g. , the temperature at which a process step is conducted
  • “about” can mean a variation of ⁇ 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 2.0, 3.0, 4.0, or 5.0 of the appropriate unit. In certain embodiments, “about” can mean a variation of ⁇ 1%, 2%, 3%, 4%, 5%, 10%, or 20%.
  • Aromatic ring system as exemplified herein, by AryA, AryB and AryC, means monocyclic, bicyclic or tricyclic aromatic ring or ring system containing 5-14 ring atoms, wherein at least one of the rings is aromatic.
  • Aromatic ring systems as used herein, encompass aryls and heteroaryls. The term may be used to describe a carbocyclic ring fused to an aryl group.
  • a 5-7-membered cycloalkyl can be fused through two adjacent ring atoms to a 5-6-membered heteroaryl containing 1, 2, or 3 heteroatom ring atoms selected from N, O, and S.
  • a heteromonocyclic ring is fused through two ring atoms to a phenyl or 5-6-membered heteroaryl containing 1, 2, or 3 heteroatoms selected from N, O, and S.
  • Aryl means a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing 6-14 carbon atoms, wherein at least one of the rings is aromatic.
  • aryl include phenyl and naphthyl.
  • Cycloalkyl means a saturated monocyclic, bicyclic or bridged carbocyclic ring, having a specified number of carbon atoms.
  • Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • “Drug resistant” means, in connection with a Mycobacterium, a Mycobacterium which is no longer susceptible to at least one previously effective drug; which has developed the ability to withstand antibiotic attack by at least one previously effective drug.
  • a drug resistant strain may relay that ability to withstand to its progeny. Said resistance may be due to random genetic mutations in the bacterial cell that alters its sensitivity to a single drug or to different drugs.
  • Halogen includes fluorine, chlorine, and bromine.
  • Heteroaryl means monocyclic, bicyclic or tricyclic ring or ring system containing 5-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, a N as a quaternary salt, S (including SO and SO 2 ) and O, wherein at least one of the heteroatom containing rings is aromatic.
  • heteroaryl examples include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzopyrazolyl, benzofuranyl, benzothiophenyl (including S-oxide and dioxide) , benzotriazolyl, furo (2, 3-b) pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, dibenzofuranyl, and the like.
  • heteroaryl is selected from: pyridine, pyrimidine, thiazole, benzimidazole, benzthiazole, benzoxazole, and benzisoxazole.
  • heteroaryl is pyridine. Examples of bicyclic rings (which are contemplated in the definition of AryA) include
  • Heterocycle as exemplified herein by HetA, HetB and HetC, means monocyclic, bicyclic or tricyclic saturated or monounsaturated ring or ring system containing 5-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, a N as a quaternary salt, S (including SO and SO 2 ) and O.
  • a heterocycle contains two rings, the rings may be fused, bridged or spirocyclic.
  • monocyclic heterocycle rings include piperazine, piperidine, and morpholine.
  • bicyclic heterocycle rings include 1, 4-diazabicyclo [2, 2, 2] octane and 2, 6-diazaspiroheptane.
  • Neargenicin compound refers to a class of structurally related compounds having tricyclic lactone containing a unique ether bridge and analogs thereof including whether the bridge is an amine.
  • nargenicin compounds include any of the compounds disclosed in Megerlein et al. , 1982, J. Antibiotics 35:254-255; Kallmerten, 1995, Studies in Natural Products Chemistry 17:283-310; and U. S. Pat. Nos.
  • Nargenicin A 1 18-deoxynargenicin A 1 , 18-deoxy-18-oxonargenicin A 1 , 18-chloro-18-deoxynargenicin A 1 , 18-azido-18-deoxynargenicin A 1 , 18-O-thiocarbonyl-1’ -imidazolenargenicin A 1 , Nargenicin B 1 , Nargenicin B 2 , Nargenicin B 3 , Nargenicin C 1 , and nodusmicin.
  • Nargenicin compounds also includes any of the compounds encompassed by formulas I, Ia, Ib, or Ic.
  • “Tuberculosis” comprises disease states usually associated with infections caused by mycobacteria species comprising M. tuberculosis complex.
  • the term “tuberculosis” is also associated with mycobacterial infections caused by mycobacteria other than M. tuberculosis (MOTT) .
  • MOTT M. tuberculosis
  • Other mycobacterial species include M. avium-intracellulare, M. kansarii, M. fortuitum, M. chelonae, M. leprae, M. africanum, and M. microti, M. avium paratuberculosis, M. intracellulare, M. scrofulaceum, M. xenopi, M. marinum, and M. ulcerans.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, sub-embodiments, aspects, classes or sub-classes, wherein the compound or its salt is in a substantially pure form.
  • substantially pure means suitably at least about 60 wt. %, typically at least about 70 wt. %, preferably at least about 80 wt.%, more preferably at least about 90 wt. %(e. g. , from about 90 wt. %to about 99 wt. %) , even more preferably at least about 95 wt. %(e. g. , from about 95 wt.
  • the level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry.
  • a compound or salt of 100%purity is one which is free of detectable impurities as determined by a standard method of analysis.
  • a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention.
  • any variable e. g. , R 1 , R a , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a squiggly line across a bond in a substituent variable represents the point of attachment.
  • substituted shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
  • substitutions can also be occur where such group is part of a larger substituent, e. g. , –C 1 - 8 alkyl-C 3 - 7 cycloalkyl and –C 1 - 8 alkyl-aryl.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of formula I.
  • different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H or D) .
  • Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the EXAMPLES herein using appropriate isotopically-enriched reagents and/or intermediates.
  • any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i. e. , any carbon atom or any heteroatom) provided that a stable compound results.
  • a heteroaromatic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range.
  • a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include asaspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms.
  • C 1 - 6 when used with a chain means that the chain can contain 1, 2, 3, 4, 5 or 6 carbon atoms. It also includes all ranges contained therein including C 1 - 5 , C 1 - 4 , C 1 - 3 , C 1 - 2 , C 2 - 6 , C 3 - 6 , C 4 - 6 , C 5 - 6 , and all other possible combinations.
  • a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e. g. , therapeutic administration to a subject) .
  • the compounds of the present invention are limited to stable compounds embraced by Formula I.
  • compound refers to the free compound and, to the extent they are stable, any hydrate or solvate thereof.
  • a hydrate is the compound complexed with water
  • a solvate is the compound complexed with an organic solvent.
  • the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e. g. , is neither toxic nor otherwise deleterious to the recipient thereof) .
  • a pharmaceutically acceptable salt can be formed, for example, by treating the compound of the invention (e. g. , a compound of Formula I) with one molar equivalent of a mild base (e. g. , sodium carbonate, sodium bicarbonate, potassium bicarbonate, or sodium acetate) .
  • M is a cation, such as Na + in the event of treatment with a sodium base.
  • the compounds of the invention can also be employed in the form of a prodrug.
  • the hydrogen in —COOH be replaced with any the following groups: C 1-6 alkyl, C 3-6 cycloalkyl, –C 1-6 alkyl-C 3-6 cycloalkyl, C 3-7 cycloheteroalkyl, –C 1-6 alkyl-C 3-7 cycloheteroalkyl, aryl, –C 1-10 alkyl-aryl, heteroaryl, and –C 1-10 alkyl-heteroaryl.
  • Any C 1-6 alkyl, C 3-6 cycloalkyl, or C 3-7 cycloheteroalkyl can also be substituted.
  • Any aryl or heteroaryl can also be substituted as indicated.
  • the present invention includes pharmaceutical compositions comprising a compound of Formula I of the present invention, optionally one or more other active components, and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier will depend on the route of administration.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other, do not interfere with the effectiveness of the active ingredient (s) , and are not deleterious (e. g. , toxic) to the recipient thereof.
  • compositions according to the invention may, in addition to the inhibitor, contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
  • the present invention includes a method for treating a bacterial infection which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • subject or, alternatively, “patient”
  • patient refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • administration and variants thereof (e. g. , "administering" a compound) in reference to a compound of Formula I mean providing the compound, or a pharmaceutically acceptable salt thereof, to the individual in need of treatment.
  • administration and its variants are each understood to include provision of the compound or its salt and the other agents at the same time or at different times.
  • agents of a combination are administered at the same time, they can be administered together in a single composition or they can be administered separately. It is understood that a"combination"of active agents can be a single composition containing all of the active agents or multiple compositions each containing one or more of the active agents.
  • a combination can be either a single composition comprising both agents or two separate compositions each comprising one of the agents; in the case of three active agents a combination can be either a single composition comprising all three agents, three separate compositions each comprising one of the agents, or two compositions one of which comprises two of the agents and the other comprises the third agent; and so forth.
  • compositions and combinations of the present invention are suitably administered in effective amounts.
  • effective amount as used herein with respect to a nargenicin compound means the amount of active compound sufficient to inhibit DnaE and/or cause a bacteriocidal or bacteriostatic effect.
  • the effective amount is a "therapeutically effective amount” meaning the amount of active compound that can overcome bacterial drug resistance and which is sufficient to inhibit bacterial replication and/or result in bacterial killing.
  • compositions of the present invention are suitably parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, intraocular, or intrarectal, wherein the composition is suitably formulated for administration by the selected route using formulation methods well known in the art, including, for example, the methods for preparing and administering formulations described in chapters 39, 41, 42, 44 and 45 in Remington –The Science and Practice of Pharmacy, 21 st edition, 2006.
  • compounds of the invention are administered intravenously in a hospital setting.
  • administration is oral in the form of a tablet or capsule or the like.
  • the dosage of the compounds of the invention and of their pharmaceutically acceptable salts may vary within wide limits and should naturally be adjusted, in each particular case, to the individual conditions and to the pathogenic agent to be controlled.
  • the daily dose may be between 0.005 mg/kg to 100 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.05 mg/kg to 5 mg/kg, 0.05 mg/kg to 1 mg/kg.
  • the compound in the invention is provided in a pharmaceutical formulation for oral, intravenous, intramuscular, nasal, or topical administration.
  • the formulation can be prepared in a dosages form, such as but not limited to, a tablet, capsule, liquid (solution or suspension) , suppository, ointment, cream, or aerosol.
  • the presently disclosed subject matter provides such compounds and/or formulations that have been lyophilized and that can be reconstituted to form pharmaceutically acceptable formulations for administration, for example, as by intravenous or intramuscular injection.
  • Intravenous administration of a compound of the invention can be conducted by reconstituting a powdered form of the compound with an acceptable solvent.
  • suitable solvents include, for example, saline solutions (e. g. , 0.9%Sodium Chloride Injection) and sterile water (e. g. , Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, or Bacteriostatic Water for Injection with 0.9%benzyl alcohol) .
  • the powdered form of the compound can be obtained by gamma-irradiation of the compound or by lyophilization of a solution of the compound, after which the powder can be stored (e. g., in a sealed vial) at or below room temperature until it is reconstituted.
  • the concentration of the compound in the reconstituted IV solution can be, for example, in a range of from about 0.1 mg/mL to about 20 mg/mL.
  • the methods of the presently disclosed subject matter are useful for treating these conditions in that they inhibit the onset, growth, or spread of the condition, cause regression of the condition, cure the condition, or otherwise improve the general well-being of a subject afflicted with, or at risk of, contracting the condition.
  • the terms “treat” , “treating” , and grammatical variations thereof, as well as the phrase “method of treating” are meant to encompass any desired therapeutic intervention, including but not limited to a method for treating an existing infection in a subject, and a method for the prophylaxis (i. e. , preventing) of infection, such as in a subject that has been exposed to a microbe as disclosed herein or that has an expectation of being exposed to a microbe as disclosed herein.
  • Infections that may be treatable by the compounds of the invention can be caused by a variety of microbes, including fungi, algae, protozoa, bacteria, and viruses.
  • the infection is a bacterial infection.
  • Exemplary microbial infections that may be treated by the methods of the invention include, but are not limited to, infections caused by one or more of Staphylococcus aureaus, Enterococcus faecalis, Bacillus anthracis, a Streptococcus species (e. g.
  • Streptococcus pyogenes and Streptococcus pneumoniae , Escherichia coli, Pseudomonas aeruginosa, Burkholderia cepacia, a Proteus species (e. g. , Proteus mirabilis and Proteus vulgaris) , Klebsiella pneumoniae, Acinetobacter baumannii, Strenotrophomonas maltophillia, Mycobacterium tuberculosis, Mycobacterium bovis, other mycobacteria of the tuberculosis complex, and non-tuberculous mycobacteria, including Mycobacterium ulcerans.
  • the infection is an infection of a gram-positive bacterium.
  • the infection is selected from a mycobacterial infection, a Bacillus anthracis infection, anEnterococcus faecalis infection, and a Streptococcus pneumoniae infection.
  • the compound of Formula (I) is administered prophylactically to prevent or reduce the incidence of one of: (a) a Mycobacterium tuberculosis infection in a subject at risk of infection; (b) a recurrence of a Mycobacterium tuberculosis infection; and (c) combinations thereof.
  • the compound of Formula (I) is administered to treat an existing Mycobacterium tuberculosis infection.
  • the compound of Formula (I) is administered to treat an infection of a multi-drug resistant strain of Mycobacterium tuberculosis (i. e.
  • the compound of Formula (I) has a minimum inhibitory concentration (MIC) against Mycobacterium tuberculosis of 25 ⁇ g/mL or less.
  • the compound of Formula (I) is administered to treat an infection of a multi-drug resistant strain of Mycobacterium tuberculosis.
  • the methods of the presently disclosed subject matter can be useful for treating these tuberculosis in that they inhibit the onset, growth, or spread of a TB infection, cause regression of the TB infection, cure the TB infection, or otherwise improve the general well-being of a subject afflicted with, or at risk of, contracting tuberculosis.
  • Subjects suffering from anM. tuberculosis or other tuberculosis-related infection can be determined via a number of techniques, e. g. , sputum smear, chest X-ray, tuberculin skin test (i. e. , Mantoux test or PPD test) and/or the presence of other clinical symptoms (e. g., chest pain, coughing blood, fever, night sweats, appetite loss, fatigue, etc. ) .
  • bacterial RNA, DNA or proteins can be isolated from a subject believed to be suffering from TB and analyzed via methods known in the art and compared to known nucleic or amino acid sequences of bacterial RNA, DNA or protein.
  • the compound of Formula I, Ia, Ib, or Ic has a minimum inhibitory concentration (MIC) against Mycobacterium tuberculosis of 25 ⁇ g/mL or less.
  • MICs can be determined via methods known in the art, for example, as described in Hurdle et al., 2008, J.Antimicrob. Chemother. 62:1037-1045.
  • the methods of the invention further comprise administering to the subject an additional therapeutic compound.
  • the compound of the invention is administered to the subject before, after, or at the same time as one or more additional therapeutic compounds.
  • the additional therapeutic compound is an antibiotic.
  • the additional therapeutic compound is an anti-tuberculosis therapeutic.
  • the additional therapeutic compound is selected from the group comprising isoniazid, ethambutol, rifampicin, kanamycin, capreomycin, linezolid, and streptomycin.
  • the invention thus provides in a further aspect, a combination comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with one or more additional therapeutic agents.
  • additional therapeutic agents are anti-tuberculosis agents including, but not limited to, amikacin, aminosalicylic acid, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, pyrazinamide, rifamycins (such as rifampin, rifapentine and rifabutin) , streptomycin, clarithromycin, azithromycin, oxazolidinones and fluoroquinolones (such as ofloxacin, ciprofloxacin, moxifloxacin and gatifloxacin) .
  • “First-line” chemotherapeutic agents used to treat a Mycobacterium tuberculosis infection that is not drug resistant include isoniazid, rifampin, ethambutol, streptomycin and pyrazinamide.
  • “Second-line” chemotherapeutic agents used to treat a Mycobacterium tuberculosis infection that has demonstrated drug resistance to one or more “first-line” drugs include ofloxacin, ciprofloxacin, ethionamide, aminosalicylic acid, cycloserine, amikacin, kanamycin and capreomycin.
  • isoniazid pyrazinamide
  • amikacin ethionamide
  • moxifloxacin
  • the one or more additional therapeutic agent is, for example, an agent useful for the treatment of tuberculosis in a mammal, therapeutic vaccines, anti-bacterial agents, anti-viral agents; antibiotics and/or agents for the treatment of HIV/AIDS.
  • therapeutic agents include isoniazid (INH) , ethambutol, rifampin, pirazinamide, streptomycin, capreomycin, ciprofloxacin and clofazimine.
  • the one or more additional therapeutic agent is a therapeutic vaccine.
  • a compound of Formula I, or a pharmaceutically acceptable salt thereof may thus be administered in conjunction with vaccination against mycobacterial infection, in particular vaccination against Mycobacterium tuberculosis infection.
  • Existing vaccines against mycobacterial infection include Bacillus Calmette Guerin (BCG) .
  • BCG Bacillus Calmette Guerin
  • Vaccines currently under development for the treatment, prophylaxis or amelioration of mycobacterial infection include: modified BCG strains which recombinantly express additional antigens, cytokines and other agents intended to improve efficacy or safety; attenuated mycobacteria which express a portfolio of antigens more similar to Mycobacterium tuberculosis than BCG; and subunit vaccines.
  • Subunit vaccines may be administered in the form of one or more individual protein antigens, or a fusion or fusions of multiple protein antigens, either of which may optionally be adjuvanted, or in the form of a polynucleotide encoding one or more individual protein antigens, or encoding a fusion or fusions of multiple protein antigens, such as where the polynucleotide is administered in an expression vector.
  • subunit vaccines include, but are not limited to: M72, a fusion protein derived from the antigens Mtb32a and Mtb39; HyVac-1, a fusion protein derived from antigen 85b and ESAT-6; HyVac-4, a fusion protein derived from antigen 85b and Tb10.4; MVA85a, a modified vaccinia virus Ankara expressing antigen 85a; and Aeras-402, adenovirus 35 expressing a fusion protein derived from antigen 85a, antigen 85b and Tb10.4.
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 1.5 hours, the reaction mixture was partitioned between ethyl acetate (50 ml) and a 0.1 M aqueous sodium bisulfite solution (30 ml) . The aqueous layer was extracted with ethyl acetate (3 x 30 ml) . The organic layers were combined, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The resulting residue was lyophlized from ethanol and benzene to give the title compound as a yellow solid, which was used in the next reaction without further purification.
  • Trichloroacetyl isocyanate (0.6 ⁇ l, 4.85 ⁇ mol) was added to a stirred solution of Nargenicin (2.5 mg, 4.85 ⁇ mol) in 1,2-dichloroethane (0.25 ml) .
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 1 hour, the reaction mixture was evaporated under reduced pressure.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 12 minute 20-100%Acetonitrile /Water gradient followed by a 6 minute Acetonitrile flush.
  • N,N'-Carbonyldiimidazole (1.3 mg, 8.02 ⁇ mol) was added to a stirred solution of Nargenicin (4.0 mg, 7.76 ⁇ mol) in 1, 2-dichloroethane (0.25 ml) .
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 5.5 hours, N-propylamine (3 ⁇ l, 0.037 mmol) was added to the reaction mixture. After an additional 16 hours, the reaction mixture was evaporated and the resulting residue was placed under high vacuum.
  • the residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Examples 3-25 were prepared according to the methods in Example 2.
  • N,N'-carbonyldiimidazole (5.7 mg, 0.035 mmol) was added to a stirred solution of Nargenicin (8.9 mg, 0.017 mmol) in 1, 2-dichloroethane (0.35 ml) .
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 1.5 hours, the reaction mixture was evaporated to give a colorless residue, which was dissolved in isopropanol (0.35 ml) to give a colorless solution.
  • 1, 3-propanediol (0.02 ml, 0.277 mmol) was added to the reaction mixture, which was heated to 50°C. After 4 days, the reaction mixture was cooled to room temperature and evaporated.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Examples 27-36 were prepared according to the methods in Example 26.
  • Nargenicin (3.9 mg, 7.56 ⁇ mol) , palladium on carbon (0.8 mg, 0.752 ⁇ mol) , and methanol (0.5 ml) were combined in a 5 ml flask.
  • the reaction mixture was degassed (3x) and purged with hydrogen before being placed under a hydrogen balloon. After 2 hours, the hydrogen balloon was removed and the reaction mixture was degassed (2x) .
  • the reaction mixture was filtered (0.45 ⁇ m syringe filter) and diluted with methanol before being purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • N,N'-carbonyldiimidazole 13.0 mg, 0.080 mmol was added to a stirred solution of (3R, 4S, 7S, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -4- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -14-hydroxy-7-methoxy-1, 3, 13-trimethyl-6-oxo-3,4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14 b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (6.9 mg, 10.95 ⁇ mol) in 1, 2-dichloroethane (0.25 ml) .
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 3 hours, ammonia was blown into the reaction mixture for 1 minute. After another 17.5 hours, additional 1, 2-dichloroethane (0.1 ml) was added and ammonia was blown into the reaction mixture for 1 minute. After an additional 22 hours, the reaction mixture was evaporated under reduced pressure. The resulting residue was dissolved in tetrahydrofuran (0.6 ml) and 2N HCl (0.1 ml) was added to the resulting solution. The reaction mixture was heated to 60°C. After 5 hours, the reaction mixture was cooled to room temperature and evaporated under reduced pressure.
  • Example 39 was prepared according to the methods in Example 38.
  • Benzenesulfonyl isocyanate (10 ⁇ l, 0.075 mmol) was added to a stirred solution of (3R, 4S, 7S, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -4- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -14-hydroxy-7-methoxy-1, 3, 13-trimethyl-6-oxo- 3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (4.9 mg, 7.78 ⁇ mol) in 1, 2-dichloroethane (0.25 ml) .
  • N-bromosuccinimide 2.5 mg, 0.014 mmol
  • benzoyl peroxide 1.1 mg, 4.54 ⁇ mol
  • the reaction mixture was an opaque suspension that was heated to 70°C. After 5 hours, the reaction mixture was cooled to room temperature and evaporated under reduced pressure.
  • the resulting residue (loaded in methanol) was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Sodium borohydride was added to the reaction mixture in 7 portions (several mgs each) over the course of an hour, resulting in vigorous gas evolution. Additional methanol (0.5 ml) was added to the reaction mixture just prior to the final portion of sodium borohydride to improve stirring. Following the final addition of sodium borohydride, the reaction mixture was warmed to room temperature and acidified with 2N HCl to a pH of 1.5-2. The reaction mixture was stirred for about 5 minutes before neutralizing with a saturated aqueous sodium bicarbonate solution. The reaction mixture was concentrated under reduced pressure to about 0.5 ml, resulting in the formation of a white residue.
  • reaction mixture was diluted with toluene (1.4 ml) .
  • the reaction mixture was added dropwise (2-3 drops /min) to a stirred solution of 4-dimethylaminepyridine (9.2 mg, 0.075 mmol) in toluene (4.4 ml) over a 52 minute period.
  • the solution became hazy and increased in haziness during the course of the addition, so that by the end of the addition the reaction mixture was almost white.
  • the reaction mixture was a yellow solution that was stirred at room temperature. After 1.5 hours, additional methylmagnesium bromide (70 ⁇ l, 0.210 mmol) was added to the reaction mixture, resulting in the immediate formation of a white precipitate. After another 1.5 hours, additional methylmagnesium bromide (35 ⁇ l, 0.105 mmol) was added to the reaction mixture. After another 30 minutes, additional methylmagnesium bromide (50 ⁇ l, 0.150 mmol) was added to the reaction mixture. After an additional 30 minutes, the reaction mixture was quenched with methanol ( ⁇ 1 ml) and evaporated under reduced pressure.
  • the reaction mixture was a pale yellow solution that was stirred at room temperature. After 40 minutes, the reaction mixture was diluted with toluene (4.25 ml) and added dropwise to a solution of 4-dimethylaminopyridine (27.8 mg, 0.228 mmol) in toluene (13.25 ml) using an addition funnel over a 38 minute period. The reaction mixture steadily increased in haziness during the course of the addition. After 30 minutes, the reaction mixture was diluted with methanol and evaporated under reduced pressure.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Examples 49-55 were prepared according to the methods in Example 48.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 12 minute 20-100%Acetonitrile /Water gradient followed by a 7 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Examples 57 and 59-67 were prepared according to the methods in Example 56.
  • the reaction mixture was a colorless solution that was heated to 75°C. After 18 hours, the reaction mixture was cooled to room temperature and evaporated under reduced pressure to give an amber residue.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 17 minute 20-100%Acetonitrile /Water gradient followed by a 2 minute Acetonitrile flush.
  • the product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • the reaction mixture was a colorless solution that was stirred at room temperature. After 4.5 hours, the reaction mixture was diluted with ethanol and evaporated under reduced pressure. The resulting residue was lyophilized from ethanol and benzene to give the title compound as a yellow solid.
  • the resulting residue was purified on a Waters Sunfire C 18, 30 x 150 mm column, eluting with Acetonitrile /Water+0.1%TFA at 20 ml /min using a 12 minute 20-100%Acetonitrile /Water gradient followed by a 7 minute Acetonitrile flush. The product fractions were combined, evaporated under reduced pressure, and lyophilized from ethanol and benzene to give the title compound as a white solid.
  • Step 1 (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13S, 14R, 14aS, 14bS, E) -14- ( (tert-butyldimethylsilyl) oxy) -4- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -7-methoxy-1, 3, 13-trimethyl-6-oxo-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1- (tert-butyldimethylsilyl) -1H-pyrrole-2-carboxylate
  • Step 2 (1R, 2R, 3S, 4R, 4aS, 5S, 6S, 8aR) -4- ( (tert-butyldimethylsilyl) oxy) -5-( (4R, 5S, 6R, E) -6- ( (tert-butyldimethylsilyl) oxy) -5-hydroxy-4-methylhept-2-en-2-yl) -6- ( (S) -3-hydroxy-2-methoxypropyl) -3-methyl-1, 2, 3, 4, 4a, 5, 6, 8a-octahydro-1, 5-epoxynaphthalen-2-yl 1H-pyrrole-2-carboxylate
  • Step 3 (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13S, 14R, 14aS, 14bS, E) -14- ( (tert-butyldimethylsilyl) oxy) -4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3,4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate and (3R, 4R, 7S, 8aS, 10aR, 11R, 12R, 13S, 14R, 14aS, 14bS, E) -14- ( (tert-butyldimethylsilyl) oxy) -4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3,4, 6, 7, 8, 8
  • Step 4 (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate and (3R, 4R, 7S, 8aS, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e
  • Ethyl amine (0.05 mL, 2 M in THF, 0.5 mmol) and acetic acid (0.02 mL, 1.05 g/mL, 0.35 mmol) were added to this mixture which was then stirred at room temperature under a nitrogen atmoshphere for 2 hours. Toluene was removed under reduced pressure. Methanol (0.1 mL) and sodium borohydride (0.5 mg, 0.1 mmol) were added to the residue and the mixture was stirred at room temperature for several minutes.
  • the crude mixture was purified by mass directed HPLC (19X100mm Waters Sunfire 5 ⁇ m, Electrospray positve detection, gradient: Water+0.05%TFA, MeCN+0.05%TFA, 10-100%over 12 min) to give (3R, 4S, 7S, 8aS, 10aR, 11R, 12S, 13S, 14R, 14aS, 14bS, E) -12- (ethylamino) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 8, 8a, 10a, 11, 12, 13, 14, 14a-decahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-6 (7H) -one (1.4 mg 2.4 ⁇ mol) as a film.
  • Step 1 (3R, 4S, 7S, 8aS, 10aR, 11R, 14aR, 14bS, E) -4- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 8, 8a, 10a, 11-hexahydro-11, 14b-epoxynaphtho [2, 1-e] oxecine-6, 14 (7H, 14aH) -dione (36 mg, 0.07 mmol) and imidazole (14 mg, 0.2 mmol) and hafnium tetrachloride (2.2 mmg, 7 ⁇ mol) were placed into a flame-dried flask.
  • Acetonitrile (0.35 mL) was added the resulting suspension was stirred under a nitrogen atmosphere for approximately 18 hours. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine and then dried over magnesium sulfate, then filtered and concentrated under reduced pressure.
  • Step 2 Sodium borohydride (3 mg, 0.07 mmol) was added to a flask containing a solution of crude (3R, 4S, 7S, 8aS, 10aR, 11R, 14aR, 14bS, E) -4- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -12- (1H-imidazol-1-yl) -7-methoxy-1, 3, 13-trimethyl-3,4, 8, 8a, 10a, 11, 12, 13-octahydro-11, 14b-epoxynaphtho [2, 1-e] oxecine-6, 14 (7H, 14aH) -dione (40 mg) in methanol (1 mL) and the resulting mixture was stirred at room temperature for 20 minutes.
  • Tetrabutylammonium fluoride (0.07 mL, 1 M, 0.07 mmol) was added and the mixture was stirred for 30 minutes at room temperature. The mixture was then concentrated under reduced pressure. The residue was purified by mass directed HPLC (19X100mm Waters Sunfire 5 ⁇ m electrospray positve detection, gradient: acetonitrile+0.05%water+0.05%TFA, TFA, 10-100%over 12 min) , and the product fractions were lyophilized to give (3R, 4S, 7S, 8aS, 10aR, 11R, 14R, 14aS, 14bS, E) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -12- (1H-imidazol-1-yl) -7-methoxy-1, 3-dimethyl-3, 4, 8, 8a, 10a, 11, 12, 13, 14, 14a-decahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-6 (7H)
  • Step 1 Ammonia in methanol (0.7 mL, 7 M, 5 mmol) was added to flask containing (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13S, 14aR, 14bS, E) -4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-6, 14-dioxo-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (30 mg, 0.06 mmol) and the reaction was stirred at room temperature for 24 hours.
  • Step 2 Methanol (0.6 mL) and then sodium borohydride (10 mg, 0.26 mmol)was added to a flask containing (3R, 4S, 7S, 8aS, 10aR, 11R, 12S, 13S, 14aR, 14bS, E) -12-amino-4-( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 8, 8a, 10a, 11, 12, 13-octahydro-11, 14b-epoxynaphth o [2, 1-e] oxecine-6, 14(7H, 14aH) -dione (25 mg, 0.06 mmol) and the resulting mixture was stirred at room temperature for 30 minutes.
  • Acetyl chloride (2 ⁇ L, 1.10 g/mL, 0.03 mmol) was added to a flask containing (3R, 4S, 7S, 8aS, 10aR, 11R, 12S, 13S, 14R, 14aS, 14bS, E) -12-amino-14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-3, 4, 8, 8a, 10a, 11, 12, 13, 14, 14a-decahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-6 (7H) -one (8 mg, 0.02 mmol) in dichloromenthane (0.1 mL) .
  • Step 1 Di (1H-imidazol-1-yl) methanethione (14 mg, 0.08 mmol) in dichloroethane (1 mL) was added to a tube containing (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-6-oxo-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (20 mg, 0.04 mmol) .
  • the vial was sealed and then heated at reflux for 20 minutes.
  • the crude reaction mixture was purified by preparative thin layer chromatography on silica (1:1 ethyl acetate:hexanes) .
  • the product band was isolated by elution with 5%methanol in dichloromethane followed by concentration under reduced pressure.
  • the resulting material was suspended in methanol and filter through an Acrodisc (0.45 micron) and the filtrate concentrated under reduced pressure.
  • Meta-chloroperbenzoic acid (2.5 mg, 0.02 mmol) was added to a vial containing (3R, 4S, 7S, 8aS, 10aR, 11R, 12R, 13R, 14R, 14aS, 14bS, E) -14-hydroxy-4- ( (R) -1-hydroxyethyl) -7-methoxy-1, 3, 13-trimethyl-6-oxo-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (5 mg, 0.01 mmol) in ethyl acetate (0.1 mL) and the mixture was stirred at room temperature for 20 hours.
  • reaction mixture was then purified by preparative thin layer chromatography on silica (1:1 ethyl acetate:hexanes) to give (1aS, 1bS, 3S, 6S, 7R, 9aS, 9bS, 10R, 11R, 12R, 13R, 13aS, 13bR, E) -10-hydroxy-6- ( (R) -1-hydroxyethyl) -3-methoxy-7, 9, 11-trimethyl-4-oxo-1a, 1b, 2, 3, 4, 6, 7, 9b, 10, 11, 12, 13, 13a, 13b-tetradecahydro-9a, 13-epoxyoxireno [2', 3':3, 4] naphtho [2, 1-e] oxecin-12-yl 1H-pyrrole-2-carboxylate (1 mg, 0.002 mmol) as a film.
  • Nitromethane (4 L, 1.13 g/mL, 0.08 mmol) was added to a solution of 2, 8, 9-tri-i-propyl-2, 5, 8, 9-tetraaza-1-phosphabicyclo [3.3.3] undecane (22 mg, 0.075 mmol) in tetrahydrofuran under an atmosphere of nitrogen.
  • Step 2 Potassium carbonate (15 mg, 0.11 mol) and then tert-butyl hydroperoxide (0.2 mL, 5 M in --, 0.1 mmol) was added to a flask containing a solution of (50 mg, 0.11 mmol) in dichloromethane (1 mL) . The resulting mixture was stirred at room temperature overnight (approximately 18 hours) . The reaction mixture was partitioned between dichloromethane and aqueous sodium bicarbonate (5%) . The organic phase was then dried over magnesium sulfate, filtered and then concentrated under reduced pressure.
  • Step 3 Sodium borohydride (1 mg, 0.03 mnmol) was added to a vial containing a solution of (3R, 4S, 7S, 8aS, 10aR, 11R, 12S, 14aR, 14bS, E) -4- ( (R) -1-hydroxyethyl) -7-methoxy-1,3, 13-trimethyl-6, 14-dioxo-3, 4, 6, 7, 8, 8a, 10a, 11, 12, 13, 14, 14a-dodecahydro-11, 14b-epoxynaphtho [2, 1-e] oxecine-12-carbaldehyde (7 mg, 0.02 mmol) in methanol (0.5 mL) .
  • Nargenicin (104mg, 0.202mmol) was dissolved in acetonitrile (3mL) and N-iodosuccinimide (45mg, 0.202mmol) was added. The mixture was stirred at room temperature for 18h. The mixture was purified by Prep HPLC using a Sunfire C 18 column and 30-100%acetonitrile/water as gradient.
  • Benzamide (20mg, 0.171mmol) , (1S, 2S) -N1, N2- dimethylcyclohexane-1, 2-diamine (9.8mg, 0.069mmol) , copper (I) iodide (6.5mg, 0.034mmol) and K 3 PO 4 (22mg, 0.103mmol) were added.
  • the mixture was heated to 100°Cin a sealed tube for 18h.
  • the cooled mixture was filtered and the residue was purified by Prep HPLC using a Sunfire C 18 column and 30-100%acetonitrile/water as gradient.
  • Plasmids encoding EcDnaE E. coli DnaE residues 1–1160
  • SaDnaE S. aureus DnaE residues 1–1065 with 6xHis N-terminal tags
  • Cells were grown in LB media to an OD ⁇ 0.45 pelleted and then resuspended in Minimal Media, as described in Pryor et al. (1997, Protein Expr Purif. 10:309-19) , and inducer (0.4 mM IPTG or 0.2%arabinose) for 21 hours at 18°Cat 220rpm.
  • Eluate was concentrated and run on a size exclusion column (SEC200, GE Healthcare) in the following buffer; 25mM HEPES, 30mM NaCl , 1mM CaCl 2 , 5%glycerol, pH 7.9. Pool SEC fractions based on SDS-PAGE run, aliquot, freeze, and store at -80°C.
  • DnaE was diluted in 50 mM potassium phosphate pH 7.5, 5 mM BME, 10%glycerol and 200 mM NaCl prior to use.
  • the purpose of the DnaE single enzyme assay is to determine the ability of compounds to inhibit the DNA polymerase III ⁇ -subunit homolog from Staphylococcus aureus or the ⁇ -subunit from Escherichia coli without the other components of the replication machinery.
  • the DnaE single enzyme assay was a modified version of the method, Standard Pol III Assay Using Activated DNA and Four dNTPs, described by Butler et al. , 2008, Methods in Molecular Medicine: New Antibiotic Targets 142:25-36.
  • Assay was set up so that 5 ⁇ l of compound is distributed to plates, 90 ⁇ l of reaction mix is added to the compound, and 5 ⁇ l of enzyme is added to start the reaction. Assays were initiated by the addition of 0.8 ⁇ g/ml E. coli or 0.05 ⁇ g/ml S. aureusDnaE, incubated for 30 min at 30 °C, and terminated by the addition of a 20%trichloroacetic acid and 0.2%sodium pyrophosphate solution. Precipitated labeled DNA was collected on Glass-fiber Filtermat A using Micro96 Harvester, and the filters were washed, dried, and counted in a Microbeta Trilux (Perkin Elmer) . Serial dilutions of compounds (in DMSO) were added to the plates before enzyme addition.
  • the purpose of the Nargenicin antibacterial assay is to determine the minimal inhibitory concentration (MIC) of nargenicinanalogs against a panel of organisms, indicating theirin vitroantibacterial activity/spectrum. MICs and kill curves were by CLSI methods (CLSI, 2005) .
  • TAB Trypticase Soy Broth
  • TSB Trypticase Soy Broth
  • TSB with 10 ⁇ g/ml tetracycline for MB5747
  • TSA+SB Trypticase Soy Agar+5%Sheep’s Blood
  • Drug dilutions were prepared at 20x the desired final drug concentration.
  • Stock solutions of test compounds are typically made at 5.12 mg/ml in 100%DMSO and when diluted 1:2 in sterile water and then 1:20 into the final micro assay give a final highest starting concentration of 128 ⁇ g/ml.
  • Samples and controls will be prepared in 50%DMSO and serially diluted 1:2 in 50%DMSO.
  • Drug was serially diluted across assay plates filled with 95 ⁇ l of Mueller Hinton Broth II (MHII, Becton Dickinson) (for MB5890 and MB5747) , 95 ⁇ l of MHII broth+50%Human serum (for MB6266) , or 95 ⁇ l of Isosensitest broth (Oxoid, for MB6357) .
  • MHII Mueller Hinton Broth II
  • Becton Dickinson for MB5890 and MB5747
  • MHII broth+50%Human serum for MB6266
  • Isosensitest broth Oxoid, for MB6357
  • the overnight inoculum was diluted as follows: 0.4 ml of ON to 39.6 ml of sterile 0.85%saline (for MB5890 and MB6266) , 0.8 ml of ON to 39.2 ml saline (for MB6355) or by prepareing a 1 MacFarland in 5 ml saline by swabbing from the TSA blood agar plate so that its density is equivalent to a 1 McFarland standard, reading tubes using the Dade Behring Turbidity reader ( ⁇ 10 8 CFU/mL) and diluting by transferring the 1 MacFarland in 5 ml saline to 35 ml saline (for MB6357) .
  • a microtiter plate viewer was used to score wells for the minimal inhibitory concentration (MIC) for each compound.
  • Representative compounds of the present invention exhibit inhibition of DnaE in this assay and/or have antibacterial activity against one or more of the tested strains.
  • representative compounds of EXAMPLES1-213 were tested in this assay and were found to have the IC 50 values and MIC 50 values shown in Table 2. Nargenicin (Nar) was used as a control.
  • Mycobacterium tuberculosis MIC determination Mycobacterium tuberculosis MIC determination:
  • Isolated Mycobacteria tuberculosis (Mtb) cells (ATCC 27294) were grown to an OD 0.2-0.3 in 7H9 medium (4.7g Middlebrook 7H9 broth, 900 mL water (double distilled) , 2 mL glycerol, and 0.5 mL Tween 80 to which was added 100 mL ADC (5 g BSA fraction V, 2 g glucose, and 0.81 g NaCl in 100 ml water) . In a 96 well plate, the compounds were serially diluted. Positive control was isoniazid. Negative control was DMSO only. 50 ⁇ l of the 1:1000 culture dilution was added to each well, approximating 1 x 10 4 bacteria per well. The plates were incubated for total of 2 weeks at 37°Cinside a zip-lock bag.
  • 7H9 medium 4.7g Middlebrook 7H9 broth, 900 mL water (double distilled) , 2 mL glycerol, and
  • the plates were read with inverted enlarging mirror plate reader and graded as either growth or no growth.
  • the MIC is the concentration that completely inhibits growth. Photos are taken of the plates at both time points.
  • Clinical isolates were selected from a batch of 21 well characterized M tuberculosis strains (see Table 3) for MIC testing of new compounds. All these strains are susceptible to the conventional anti-tuberculosis drugs.
  • M. tuberculosis H37Rv strain was used and rifampin or isoniazid was included as the positive drug control. Normally all strains in Batch 1 were grown and then the ones that grow satisfactoryily regarding OD, purity etc. were used.
  • a pure culture of a single M. tuberculosis colony in 7H9 media was grown to OD 600nm of ⁇ 0.5 equivalent to 10 8 colony forming units/ml. 1 ml aliquots were frozen at -20 °Cand one sample was used each time to start a 10 ml culture for MIC testing. The culture was grown for 3 days to OD 600nm of ⁇ 0.3 and diluted 1: 500 for the MIC assay
  • the tested compounds were dissolved in sterile DMSO to a 20x stock (12.8 mM) amd left at room temperature for about 30 min (sometimes longer with intermittent vortexing to ensure that the compound is dissolved completely) .
  • the 12.8mM stock was diluted in 7H9 to make a 640 ⁇ M working stock for the MIC assay
  • the plates were incubated in a CO 2 incubator and read by eye after 7 days and again after 14 days by simply looking at the plate and scoring the pellets as either growth (+++) , no growth (-) or partial growth (+/-) if ⁇ 50%, on the record sheet.
  • An inverted plate reader which is basically an enlarging mirror that is placed below the plate to look at the cell pellets can also be used.
  • the last row in the dilution series that does not demonstrate growth represents the Minimum Inhibitory Concentration (MIC 99 ) of the compound.
  • Representative compounds of the present invention display antimycobacterial activity.
  • compounds of EXAMPLES90, 94, 100, 108, 109, 118, and 204 were determined to have MICs equal to or better than nargenicin.

Abstract

La présente invention concerne de nouveaux composés apparentés à la nargénicine qui peuvent inhiber une DnaE et présentent une activité antibactérienne, en particulier une activité antimycobactérienne, contre Mycobacterium tuberculosis. La présente invention concerne également une méthode permettant d'inhiber la croissance de cellules mycobactériennes ainsi qu'une méthode de traitement d'infections mycobactériennes par Mycobacterium tuberculosis par l'administration d'une quantité efficace sur le plan antimycobactérien de nargénicine ou d'un composé apparenté à la nargénicine et/ou de leurs sels pharmaceutiquement acceptables.
PCT/CN2014/089204 2014-10-22 2014-10-22 Composés nargénicine et leurs utilisations de comme agents antibactériens WO2016061772A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PCT/CN2014/089204 WO2016061772A1 (fr) 2014-10-22 2014-10-22 Composés nargénicine et leurs utilisations de comme agents antibactériens
KR1020177013260A KR20170070197A (ko) 2014-10-22 2015-10-21 나르제니신 화합물 및 항박테리아제로서의 그의 용도
EP15853228.3A EP3209667A4 (fr) 2014-10-22 2015-10-21 Composés de nargénicine et leurs utilisations en tant qu'agents antibactériens
CA2964377A CA2964377A1 (fr) 2014-10-22 2015-10-21 Composes de nargenicine et leurs utilisations en tant qu'agents antibacteriens
BR112017008101A BR112017008101A2 (pt) 2014-10-22 2015-10-21 composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
MX2017005271A MX2017005271A (es) 2014-10-22 2015-10-21 Compuestos de nargenicina y sus usos como agentes antibacterianos.
RU2017117253A RU2017117253A (ru) 2014-10-22 2015-10-21 Наргенициновые соединения и их применение в качестве антибактериальных средств
US15/517,570 US9944654B2 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents
PCT/US2015/056627 WO2016064982A1 (fr) 2014-10-22 2015-10-21 Composés de nargénicine et leurs utilisations en tant qu'agents antibactériens
CN201580069971.4A CN107108646A (zh) 2014-10-22 2015-10-21 阿根诺卡菌素类化合物及其作为抗菌剂的用途
AU2015335992A AU2015335992A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents
JP2017521550A JP2017533200A (ja) 2014-10-22 2015-10-21 ナルゲニシン化合物及び抗菌剤としてのそれの使用
US15/910,571 US10144741B2 (en) 2014-10-22 2018-03-02 Nargenicin compounds and uses thereof as antibacterial agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/089204 WO2016061772A1 (fr) 2014-10-22 2014-10-22 Composés nargénicine et leurs utilisations de comme agents antibactériens

Publications (1)

Publication Number Publication Date
WO2016061772A1 true WO2016061772A1 (fr) 2016-04-28

Family

ID=55760063

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2014/089204 WO2016061772A1 (fr) 2014-10-22 2014-10-22 Composés nargénicine et leurs utilisations de comme agents antibactériens
PCT/US2015/056627 WO2016064982A1 (fr) 2014-10-22 2015-10-21 Composés de nargénicine et leurs utilisations en tant qu'agents antibactériens

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2015/056627 WO2016064982A1 (fr) 2014-10-22 2015-10-21 Composés de nargénicine et leurs utilisations en tant qu'agents antibactériens

Country Status (11)

Country Link
US (2) US9944654B2 (fr)
EP (1) EP3209667A4 (fr)
JP (1) JP2017533200A (fr)
KR (1) KR20170070197A (fr)
CN (1) CN107108646A (fr)
AU (1) AU2015335992A1 (fr)
BR (1) BR112017008101A2 (fr)
CA (1) CA2964377A1 (fr)
MX (1) MX2017005271A (fr)
RU (1) RU2017117253A (fr)
WO (2) WO2016061772A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944654B2 (en) 2014-10-22 2018-04-17 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1
WO2004014897A1 (fr) 2002-08-12 2004-02-19 Pharmacia & Upjohn Company Llc N-aryl-2-oxazolidinones et leurs derives
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
KR20050084010A (ko) 2002-11-28 2005-08-26 아스트라제네카 아베 항균제로서의 옥사졸리디논
JP2007500707A (ja) 2003-07-29 2007-01-18 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20080021071A1 (en) 2004-05-25 2008-01-24 Astrazeneca Ab 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
WO2007133803A2 (fr) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Traitement d'infections mycobactériennes
WO2008069619A1 (fr) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Nouveaux dérivés oxazolidinones, leur procédé de preparation et composition pharmaceutique en contenant
WO2011139832A2 (fr) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Méthode de traitement des infections mycobactériennes
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (fr) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Composés nargénicine et leurs utilisations de comme agents antibactériens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SNYDER, WILLIAM C. ET AL.: "Biosynthesis of nargenicin and nodusmicin", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 106, no. 3, 31 December 1984 (1984-12-31), pages 787 - 789 *
WHALEY, H. A. ET AL.: "Nodusmicin: the structure of a new antibiotic", TETRAHEDRON LETTERS, vol. 21, no. 38, 31 December 1980 (1980-12-31), pages 3659 - 3662 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944654B2 (en) 2014-10-22 2018-04-17 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
US10144741B2 (en) 2014-10-22 2018-12-04 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Also Published As

Publication number Publication date
JP2017533200A (ja) 2017-11-09
MX2017005271A (es) 2017-08-15
US10144741B2 (en) 2018-12-04
RU2017117253A (ru) 2018-11-23
CN107108646A (zh) 2017-08-29
US9944654B2 (en) 2018-04-17
AU2015335992A1 (en) 2017-04-20
WO2016064982A1 (fr) 2016-04-28
KR20170070197A (ko) 2017-06-21
CA2964377A1 (fr) 2016-04-28
EP3209667A1 (fr) 2017-08-30
BR112017008101A2 (pt) 2018-02-20
US20180186808A1 (en) 2018-07-05
EP3209667A4 (fr) 2018-06-06
RU2017117253A3 (fr) 2019-04-16
US20170305924A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
AU2014268477A1 (en) Compounds for treatment of drug resistant and persistent tuberculosis
AU2017228870A1 (en) Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN108137574B (zh) 羟烷基噻二唑衍生物
KR20170117156A (ko) 벤즈옥사보롤 화합물 및 이의 용도
WO2021184339A1 (fr) Composé d'oxazolidinone et procédés d'utilisation de celui-ci comme agent antibactérien
US10144741B2 (en) Nargenicin compounds and uses thereof as antibacterial agents
KR20200005586A (ko) 박테리아 감염을 치료하는 화합물 및 방법
EP3914587A1 (fr) Composés d'oxazolidinone et leurs procédés d'utilisation comme agents antibactériens
US10752621B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
AU2020300400B2 (en) Compounds and methods of use thereof as antibacterial agents
CN111527093B (zh) 抗菌杂环化合物及其合成
RU2794494C2 (ru) Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14904222

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14904222

Country of ref document: EP

Kind code of ref document: A1